VERAXA Biotech AG (NASDAQ: VRXA) has appointed Carl von Halem as interim chief financial officer, effective immediately, succeeding Torsten Bürgermeister. The company announced it is in the final stages of discussions with a permanent CFO candidate expected to support its next phase of expansion and operational growth, with an update to be provided in due course.
Von Halem currently serves as chief financial officer of Xlife Sciences and played a key role in VERAXA’s public listing. The company cited his experience in corporate finance, life sciences and technology-driven businesses, as well as his familiarity with VERAXA’s operations and strategic development, as key qualifications for leading the finance function during the transition. His appointment ensures continuity in financial leadership as the company advances its pipeline of antibody-based therapeutics.
VERAXA is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
This leadership transition comes at a critical time for VERAXA as it seeks to scale operations and bring its innovative therapies to market. The appointment of a seasoned finance executive like Von Halem, who is already familiar with the company’s strategic direction, provides stability while the board evaluates permanent candidates. Investors will be watching for further updates on the permanent CFO appointment, which is expected to align with the company’s growth trajectory.
For more information on VERAXA’s recent news, visit the company’s newsroom at http://nnw.fm/VRXA. The full press release can be viewed at https://nnw.fm/BjjY6.
